RevolutionLogo.png
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
July 13, 2022 07:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Start Line in San Francisco CCC 2021
Arthritis Foundation Adds Arthritis Challenge Experience to the 2022 California Coast Classic Bicycle Tour, Presented by Amgen LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Organizers of the 2022 California Coast Classic Bicycle Tour + Arthritis Challenge Experience presented by Amgen, today announced that 70 spaces...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 10, 2021 16:05 ET | Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
BES_Mark.jpg
FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm
March 04, 2021 12:02 ET | Bragar Eagel & Squire
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
RevolutionLogo.png
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
June 09, 2020 07:30 ET | Revolution Medicines, Inc.
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) --...
Toronto Innovation A
Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen
September 09, 2019 07:00 ET | Toronto Innovation Acceleration Partners
Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
April 17, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
400dpiLogoCropped.jpg
Innovest Global Provides Acquisition Update: Authority National Supply Closing Rescheduled to First Week of November and Secured LOI for $12 Million Revenue and Profitable Acquisition in the Building Industry
October 26, 2018 09:28 ET | Innovest Global, Inc
CLEVELAND, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a conglomerate with operations in commercial and industrial products and...
400dpiLogoCropped.jpg
Innovest Global: Record Sales, Major Clients, Significant Growth Mark 1st Half 2018 Letter to Shareholders, Q2 Report
July 23, 2018 07:50 ET | Innovest Global, Inc
CLEVELAND, July 23, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Pink Current:IVST) (the “Company” or “Innovest”), posted Q2 financial reports this morning, and the following Shareholder...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
December 13, 2017 13:13 ET | Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...